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a  b  s  t  r  a  c  t
In  the  present  study,  boron  nitride  nanotubes  (BNNTs)  were  synthesized  from  an  innovative  process
and  functionalized  with  a  glycol  chitosan  polymer  in  CDTN  (Centro  de  Desenvolvimento  da  Tecnologia
Nuclear)  laboratories.  As  a means  of studying  their  in  vivo  biodistribution  behavior,  these  nanotubes
were  radiolabeled  with 99mTc and injected  in mice.  Their  size,  distribution,  and homogeneity  were  deter-
mined  by  photon  correlation  spectroscopy  (PCS),  while  their zeta  potential  was  determined  by laser
Doppler  anemometry.  The  morphology  and  structural  organization  were  evaluated  by  scanning  electron
microscopy  (SEM).  The  functionalization  in  the  nanotubes  was  evaluated  by thermogravimetry  analysis
(TGA)  and  Fourier  transformer  infrared  spectroscopy.  The  results  showed  that  BNNTs  were  obtained  andhysicochemical characterization
iodistribution  study and scintigraphic
mage
functionalized  successfully,  reaching  a mean  size  and  dispersity  deemed  adequate  for  in vivo  studies.  The
BNNTs  were  also  evaluated  by ex  vivo  biodistribution  studies  and scintigraphic  imaging  in healthy  mice.
The  results  showed  that  nanostructures,  after  24  h,  having  accumulated  in  the  liver,  spleen  and  gut, and
eliminated  via  renal  excretion.  The  ﬁndings  from  this  study  reveal  a potential  application  of  functional-
ized  BNNTs  as  new  potential  drugs  or radioisotope  nanocarriers  to  be  applied  in  therapeutic  procedures.. Introduction
The use of nanotechnology in the therapy of many diseases
as been the target of many research activities, development, and
nnovation throughout industrialized countries worldwide (Huynh
t al., 2009; Sakamoto et al., 2010). Nanostructured systems based
n carbon, silica, gold, and metal oxides that integrate differ-
nt forms, such as nanotubes, nanorods, nanowires, nanocages,
anoshells, and nanodisks, have been studied and applied to bio-
ogical systems, especially from the functionalization (coating)
ith organic molecules, peptides, DNA fragments, antibodies, or
ydrophilic polymers (Hocine et al., 2010; Klumpp et al., 2006). In
his context, the functionalization process plays an important role
n these nanostructures, improving the dispersibility in an aque-
us medium and changing the in vivo biodistribution proﬁle (Guo
t al., 2007; Xiong et al., 2009). Several works published in recent
ecades have shown that the functionalization, or coating pro-
ess, in different nanostructures using high hydrophilic molecules,
ike polyethylene glycol (PEG), can signiﬁcantly increase their
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circulation time in the blood stream, in turn minimizing the
aggregation of serum proteins, consequently reducing their identi-
ﬁcation by cells from the mononuclear phagocyte system (Saﬁ et al.,
2011; Vauthier et al., 2011). More recent studies have shown that
the functionalization of nanostructures with speciﬁc molecules,
such as folic acid or peptides (bombesin, for example), allows
for these nanostructures to be more selectively accumulated in
tumor cells, as compared to other non-target tissues. As such,
these systems can be considered promising new carriers of drugs
or radioisotopes with a high-speciﬁcity of action (de Barros et al.,
2010; Soares et al., 2011).
Although this new approach appears to be the most effective
means through which to improve the selectivity of nanostruc-
tured carriers for tumors, the passive tumor accumulation, using
the EPR (enhanced permeability and retention) effect, still remains
as an important mechanism of nanoparticle accumulation in solid
tumors, which is considered to be both a landmark principle
in tumor-targeting chemotherapy and an increasingly promising
paradigm for anticancer drug development (Fang et al., 2011;
Open access under the Elsevier OA license.Maeda et al., 2009; Torchilin, 2011). Considering the EPR effect
and the functionalization process as tools employed to improve
tumor accumulation, several papers have been published showing
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mong these systems, silica nanoparticles and carbon nanotubes
ffer promising results (Deng et al., 2011; Slowing et al., 2008). Fol-
owing the same objectives, recent works have presented boron
itride nanotubes (BNNTs) as new and safe drug delivery systems
Ciofani, 2010; Ciofani et al., 2009). These nanotubes are a struc-
ural analog of a carbon nanotube where C atoms are substituted
y alternating B and N atoms in a resonance hybrid that shows
igh structural stability; anti-oxidative ability; as well as chemical,
lectrical, and mechanical properties that are better than carbon
anotubes (Golberg et al., 2007).
Considering the fact that in vivo studies with boron nitride nano-
ubes have yet to be conducted and based on the context of the EPR
ffect and the improvement of dispersivity in an aqueous medium,
n the present work, these nanotubes were synthesized from a spe-
ial and facile synthesis route with remarkable yield developed in
ur laboratory and functionalized using a glycol chitosan polymer
ccording to procedures conducted by Ciofani et al. (2008).  After,
oth physicochemical and morphological characterizations were
erformed. In addition, ex vivo biodistribution and scintigraphic
maging studies, after IV injection, were carried out in an attempt
o evaluate their potential as drugs or radioisotope nanocarriers to
e applied in therapeutic procedures.
. Experimental
.1. Materials
Amorphous boron powder, ammonium nitrate, hematite, and
lycol chitosan (MW  = 2.5 × 105 Da, degree of deacetylation = 88%)
ere obtained from Sigma–Aldrich (São-Paulo-Brazil). All solvents
sed in this study were of analytical grade. All other chemicals used
n this study were available commercially at a reagent grade and
ere used without further puriﬁcation. MilliQ® water (simplic-
ty 185, Millipore, Bedford, USA) was used throughout the study.
ll animal experimental protocols were approved by the Ethics
ommittee for Animal Experiments (CETEA) from the Federal Uni-
ersity of Minas Gerais under the code 237/11 and comply with the
equirements of the guide for care and use of laboratory animals
ecommended by the Institute of Laboratory Animal Resources.
.2. Methods
.2.1. BNNTs preparation and functionalization
BNNTs samples were prepared based in methods described by
ang et al., 2001 (Tang et al., 2001) with modiﬁcations. The powders
f NH4NO3 (95%, w/w), amorphous boron (97%, w/w), and hematite
95%, w/w and particle size less than 50 nm)  were mixed at a molar
atio of 15:15:1, respectively, placed in tubular furnace and heated
o 550 ◦C using an alumina boat as a support. This temperature was
ept constant for 1 h. After, the temperature was raised to 1300 ◦C
nder a nitrogen gas ﬂow. These conditions were maintained for
 h. Next, the gas nitrogen ﬂow was interrupted and an ammonia
as ﬂow (50 cm3 s−1) was added, with samples treated for one addi-
ional hour. After having completed these steps, the BNNTs were
ooled and successfully obtained with a high yield.
The BNNTs were functionalized (noncovalent coating) with a
lycol chitosan polymer, based on the methods described by Ciofani
t al. (2010).  In a round-bottom ﬂask, 10 mg  of BNNTs and 20 mg  of
lycol chitosan were solubilized in 20 mL  of ethanol (99% w/w)  and
tirred at 70 ◦C, under reﬂux for 24 h. After the centrifugation pro-
ess (10,000 rpm for 10 min), the nanostructures were dispersed
n water, where an aqueous dispersion with a concentration of
.1 mg/mL  was obtained. The samples were sonicated for 15 min
Cole Parmer sonicator 750) using an output energy of 10,000 J, Pharmaceutics 423 (2012) 489– 495
resulting in a stable dispersion of BNNTs functionalized with glycol
chitosan.
2.2.2. BNNTs physicochemical characterization
2.2.2.1. Scanning electron microscopy (SEM). The morphological
characteristics of functionalized BNNTs were studied using the SEM
technique. The procedure was  performed in a scanning electron
microscope (JEOL JSM, 840A) operating at 15 kV. Samples (10 L)
were deposited, spread on silicon substrate and dried with an argon
stream. The images were obtained in electron secondary mode,
where a minimum of 10 images from each sample was analyzed
to assure reproducible results.
2.2.2.2. Thermogravimetry analysis (TGA). Aimed at evaluating the
presence of any glycol chitosan polymer under the surface of the
BNNTs and its percentage, TGA measurements were taken by a Shi-
madzu TGA 50WS at a temperature ranging from 25 to 1000 ◦C.
Approximately 3.0 mg  of a started mixture and a ﬁnal sample were
analyzed using a heating rate of 10 ◦C min−1, with a Helium (He)
atmosphere ﬂow of 20 mL  min−1 and an open alumina cell.
2.2.2.3. Fourier transform infrared spectroscopy (FTIR). The FTIR
measurements were conducted to complement the results
obtained from thermal analysis experiments. The procedure was
conducted in a PerkinElmer 1760-X spectrophotometer in the
range from 4000 to 400 cm−1 with 64 scans and 4 cm−1 of reso-
lution.
2.2.2.4. Photon correlation spectroscopy (PCS) and zeta potential
analysis. This analytical procedure allows one to determine the
mean length of the nanotubes and the polydispersity index (PDI),
which is a dimensionless measure of the broadness of the particle
size distribution. The analytical procedure was  conducted in a Zeta-
sizer Nanoseries Zs (Malvern Instruments, Malvern, UK) apparatus
after its adequate dilution in ultra-pure MilliQ® water. The results
are expressed as mean ± standard deviation for at least three dif-
ferent batches of each nanotube preparation. The zeta potential
was determined by Laser Doppler Anemometry (LDA) in the same
Zetasizer equipment. The samples of nanotubes were analyzed fol-
lowing a dilution of 1/1000 in 1 mM of NaCl at a conductivity
of approximately 120 ± 20 S/cm2. The results are reported as the
mean ± standard deviation of at least three different batches of each
liposome formulation.
2.2.3. BNNTs labeling procedure
The BNNTs were radiolabeled according to the following pro-
cedure: 1 mL  of BNNTs aqueous solution (1 mg/mL), 10 L of SnCl2
solution in HCl (1 mg/mL), and 10 L of NaHB4 solution in NaOH
(5 mg/mL) were added to a penicillin ﬂask. The pH was  adjusted
to 3, 4, 6, 7, 8, 9, 10, and 11, using either NaOH (0.1 N) or HCl
(0.1 N) depending on the experiment. Afterwards, a vacuum was
made in the ﬂask, and a solution of Na99mTcO4 (37MBq) was added
to the mixture. The ﬁnal solution was stirred at 97 ◦C for 30 min.
The radiolabeling yield of 99mTc-BNTTs was  determined by means
of instant thin layer chromatography (ITLC) in two  solvent sys-
tems: methylethylketone (MEK) to determine TcO4− and saline to
determine TcO2.
2.2.4. Biodistribution studies
Biodistribution studies were conducted using two differentprotocols: (1) ex vivo biodistribution study and (2) scintigraphic
imaging study and subsequent sacriﬁce. The studies were con-
ducted based on glycol-chitosan BNNTs radiolabeled with 99mTc
with a radiochemical purity of more than 98%.









































Fig. 1. Samples of BNNTs added in an aqueous solution. On the left cuvette, the BNNT
dispersion was not submitted to the functionalization process. On the right cuvette,
the BNNTs were functionalized with a glycol chitosan polymer. The presence of theD.C.F. Soares et al. / International Jou
.2.4.1. Ex vivo biodistribution study. Samples of 99mTc-BNNTs
40 mg/kg) were injected intravenously into the tail of Swiss mice.
fter periods of 10 and 30 min, and one and 24 h, each ani-
al  (three per group) was anesthetized intraperitoneally with
 mixture of ketamine and xylazine at a dose of 40 mg/kg and
 mg/kg, respectively. The blood was collected immediately by
ardiac puncture, and the mice were sacriﬁced by cervical dis-
ocation. The lungs, bladder, intestine, spleen, liver, and kidneys
ere collected, washed with distilled water, dried on ﬁlter paper,
nd weighed. The determination of radioactivity present in the
rgans was achieved through automatic scintillation (2470 WIZ-
RD2 Automatic Gamma  Counter). The readings were conducted
ithin the 130–150 keV energy window for 10 min. The radioac-
ivity contained in each organ was divided by its mass to furnish
he radioactivity in counts per minute per gram of tissue (cpm/g).
o set the radioactive decay of 99mTc, a separate tube with the
tandard dose containing the same activity and volume of the
ose injected into animals was deﬁned as 100% of radioactiv-
ty. The %ID/g ratio of tissue was obtained from the relationship
etween the radioactivity measured in tissue and the radioactiv-
ty measured in the standard. The data were statistically analyzed
y means of analysis of variance (ANOVA) using a PRISM 5.0
oftware.
.2.4.2. Scintigraphic imaging biodistribution study. For the scinti-
raphic imaging study, BNTTs samples were prepared and
adiolabeled to obtain enough activity to acquire the images. The
nimals were anesthetized intraperitoneally with a ketamine and
ylazine solution at a dose of 40 mg/kg and 5 mg/kg, respectively,
nd were then placed on the table in a supine position so that the
etector could be positioned on the anterior region of the animal.
he images were obtained with a gamma  camera with a collimator-
ype LEPH 128 ×128 × 32 arrays and an acquisition time of 10 min.
welve animals were used and all images were obtained from the
nimals 10 and 30 min; 1, 4 and 24 h after the administration of
1 MBq  (40 mg/kg) of radiolabeled BNNTs.
. Statistical analysis
All experiments were performed in triplicate and expressed as
ean ± standard deviation, unless otherwise stated. Mean size and
eta potential data within each time period were compared by
eans of the ANOVA test, using the software prism 5.0 and con-
idering a probability of 5% as signiﬁcant.
Fig. 2. SEM images of BNNTs before (a) and polymer on BNNTs signiﬁcantly improved the dispersivity of the system.
4. Results and discussion
4.1. BNNTs physicochemical characterization
Fig. 1 shows two  different cuvettes where BNNTs samples were
added to a volume of 500 L of water. On the left cuvette, the non-
functionalized BNNTs can be observed in a gross dispersion. Here
it becomes possible to verify the lower dispersivity of nanostruc-
tures in an aqueous solution, forming particle aggregates that are
visible to the naked eye, with a strong tendency to deposit on the
bottom of ﬂask. The cuvette on the right presents samples of BNNTs
functionalized with a glycol chitosan polymer. The polymer coating
signiﬁcantly improved the dispersity of the nanostructures, thus
enabling in vivo applications.
4.1.1. Scanning electron microscopy
Fig. 2a shows an image of pure BNNTs obtained in our laboratory,
whose dimensions are approximately 10 m in length and 70 nm in
diameter. Notably, these are commonly entangled together. Fig. 2b
shows that the glycol chitosan that coats the BNNT dispersions
after the functionalization process (b).
492 D.C.F. Soares et al. / International Journal of Pharmaceutics 423 (2012) 489– 495















































Physicochemical characteristics of the functionalized BNTTs.




 Potential ± SD
(mV)c
290 ± 11 0.18 ± 0.04 −12.4 ± 3.43ig. 3. Thermogravimetric curves of BNNTs before (a) and after (b) the functional-
zation process.
esulted in remarkably stable and well-dispersed pieces of approx-
mately 300 nm in length and 90 nm in diameter. This considerable
ncrease in the BNNT diameter indicates the efﬁciency of the func-
ionalization process.
.1.2. Thermogravimetry analysis
The amount of polymer grafted in the BNNT host was deter-
ined by thermogravimetry analysis. The weight loss of the hybrid
as evaluated within the range of 25–800 ◦C. The TGA curves of
oth samples, pure (a) and functionalized (b), are shown in Fig. 3.
igniﬁcant weight loss can be observed in the temperature range
etween 180 ◦C and 550 ◦C, corresponding to 60% of the respective
nitial masses. This ﬁnding may  be associated with the degradation
f the chitosan glycol chains attached to the BNNTs samples.
.1.3. Fourier transform infrared spectroscopy
Fig. 4 shows the FTIR spectra of glycol chitosan, as well as
ure and functionalized BNNT samples. Peak assignments of gly-
ol chitosan (a) are as follows: 3427 cm−1 (O H stretch overlapped
ith N H stretch), 2926 cm−1 (C H stretch), 1650 cm−1 (amide I
and, C O stretch of acetyl group), 1420–1380 cm−1 (C H bend),
066 cm−1 (C O stretch) (Yu et al., 2008). In Fig. 4b, the BNNT
ample exhibits a strong asymmetric band centered at 1380 cm−1,
hich corresponds to the bond B N stretch, along with a less

















 Glycol  Chitosan
 BNN T + Glycol  Chitosan
 BNN T
ig. 4. Infrared spectrum of glycol chitosan (a), BNNT (b), and BNNT + glycol chitosan
c).a Standard deviation (n = 3) of the population that was  reported by the instrument.
b Monodispersed samples (≤0.3).
c Measurement after 1:1000 dilution in 1 mM NaCl (conductivity, 120 ± 20 S/cm).
intense band at 790 cm−1 attributed to B N B bond (Zheng et al.,
2008). It can be observed that some characteristic stretching and
bending vibrations present in the glycol chitosan, such as 2926,
2860, and 1370 cm−1, are observed in the functionalized FTIR spec-
trum sample in Fig. 4c. These results prove the presence of glycol
chitosan in the BNNT matrix and demonstrate the successful func-
tionalized procedure used.
4.1.4. Photon correlation spectroscopy and zeta potential analysis
The photon correlation spectroscopy was conducted on 3 sam-
ples at different times. The results were calculated from three
independent samples by software provided by the manufacturer,
which revealed a nearly constant length of nanotubes at 290 nm
(Table 1). The PDI found in this study is presented in Table 1. All
samples presented a PDI of below 0.3. These results indicate that
the process used in nanotube preparation and functionalization
allows one to obtain a monodispersed system (<0.3) (de Assis et al.,
2008;). The zeta potential of nanotubes can predict its fate in vivo,
given that the presence of electrical charges minimizes agglomera-
tion and fusion phenomena (Casals et al., 2003). The zeta potential
from the formulation exhibited a negative charge, with values of
−12 ± 3.7 mV (Table 1).
The zeta potential in cell biology has commonly been used to
study many processes in cells, such as activation, agglutination, and
adhesion. A study conducted by Cook and Jacobson (1968) showed
signiﬁcant differences in surface electrokinetic properties between
normal and cancer cells. Recently, Zhang et al. (2008) reported a
signiﬁcant reduction in the zeta potential values between normal
breast epithelial cells and cancer breast epithelial cells (MCF7). The
signiﬁcant differences in the change in surface charges indicate
the latent role of zeta potential as a valuable biological signature
in studying the cellular interaction of nanoparticles, as well as
speciﬁc cell functionality. Nanostructures containing signiﬁcantly
positive or negative zeta potential suffer fewer aggregations and
merge among themselves, due to the appearance of electrostatic
repulsion. Furthermore, the superﬁcial charge of nanostructures
has proven to be an important pharmacokinetics regulatory prop-
erty. For example, studies show that cationic or anionic liposomes
activate the complement system through classic or alternative
pathway, respectively, leading to a blood serum protein opsoniza-
tion and subsequent phagocytosis by SMF  cells (Chonn et al., 1991).
4.2. BNNTs labeling procedure
Following the described procedure, the BNNTs were radiola-
beled in different pHs. Kean and Thanou (2010) observed that
chitosan nanoparticles were adsorbed onto the colloidal tin oxides
formed by stannous chloride used in the radiolabeling procedure.
As such, the authors opted to use sodium borohydride together
with stannous chloride to prevent the formation of colloidal parti-
cles. According to the authors, this method improved the kinetics
of the nanoparticles, resulting in both less blood clearance and liver
accumulation. The results show that in acid or alkaline the radiola-
bel yield decreases signiﬁcantly when compared to that obtained
in neutral pH in which the yield value was greater than 98%, as
described in Fig. 5.
D.C.F. Soares et al. / International Journal of




















































oFig. 5. The inﬂuence of pH on the radiolabeling yield of 99mTc-BNNTs.
.3. Biodistribution studies
.3.1. Ex vivo biodistribution study
The investigation of the destination in vivo (mice) of BNNTs
unctionalized with a glycol chitosan polymer was conducted in
his study to evaluate the capabilities of this new nanostructure
ystem as a potential carrier system for drugs and radioisotopes
or therapeutic purposes. When considering the biodistribution of
unctionalized BNNTs with glycol chitosan, one must pay attention
o the fact that their destination in vivo more greatly depends on the
olymer coating characteristics than on the bulk of base material
nd other factors, including shape, size, PDI, and zeta potential. The
x vivo biodistribution study is shown in Fig. 6. The results show
hat, after 30 min, the nanostructures reached systemic circulation
nd were captured mainly in the liver, spleen, and intestinal tissues,
n addition to a signiﬁcant accumulation in the bladder. This behav-
or was also observed at times of 1 and 4 h after injection, reﬂecting
n important excretion behavior. It is known that nanostructured
ystems are taken up by cells of the MPS, which are widely present
n the liver, spleen, although the formulations have a hydrophilic
olymer of glycol-chitosan coating the nanotubes. These results
re consistent with data published by Hyung Park et al. (2006) in a
revious study performed with glycol chitosan nanoparticles.
ig. 6. Biodistribution proﬁle in different tissues at the times: 30 min, 1, 4 and 24 h
f  glycol chitosan BNNTs. Values expressed as mean ± SD. Pharmaceutics 423 (2012) 489– 495 493
The brain and heart were also investigated. However, the
radioactivity encountered in these tissues is close to background
radiation demonstrating that BNNTs were accumulated in these
tissues (data no presented).
One hour after injection, it could be observed that only a small
portion of the injected dose remained in the blood tissue (0.79%
ID/g), which therefore accumulated in different organs and ani-
mal  tissues. This result reveals that, in spite of the very hydrophilic
character of the glycol chitosan coating, it does not provide the
system with a long circulation time, as can be observed in nanos-
tructures, such as “stealth liposomes”, where the circulation time
is signiﬁcantly extended by coating the nanostructure with a poly-
mer  that is also very hydrophilic, such as PEG (Immordino et al.,
2006). This behavior can be explained by the fact that the nanos-
tructures have been extensively excreted by urine and signiﬁcantly
captured by liver and spleen tissues, thus demonstrating the pro-
cess of identiﬁcation and phagocytosis by MPS  cells. These results
are consistent with data published by Banerjee et al. (2002),  where
glycol chitosan nanoparticles were accumulated, to a great extent,
in the liver and spleen tissue. In the same study, the authors also
found that, within 6 h after injection, glycol chitosan nanostruc-
tures undergo an increasing accumulation in the stomach. In this
present study, the equal behavior was  observed within 4 h post-
injection, contributing to the understanding that glycol chitosan
coating signiﬁcantly impacts the BNNTs destination target in vivo.
After 24 h, a low percentage of the injected dose could be
observed in all studied organs. This conduct can be explained
in part by the high rate of elimination through renal excre-
tion observed and in part by the fact that chitosan and its
derivates can be degraded by enzymes such as glucosamine–N-
acetyl-glucosamine, hydrolysis glucosamine–glucosamine and
N-acetyl-glucosamine–N-acetyl-glucosamine (Kean and Thanou,
2009). Glycol chitosan is thought to be predominantly degraded in
vertebrates by lysozymes. In humans, eight chitinases (in the gly-
coside hydrolase, family 18) have been identiﬁed, three of which
have shown enzymatic activity (Funkhouser and Aronson, 2007;
Zhang and Neau, 2002).
The BNNTs are inorganic nanostructures that cannot be metab-
olized in the human body. Thus, the most plausible explanation
for their clearance from the liver, spleen, and intestines is related
to a possible metabolic action performed exclusively with a glycol
chitosan coating over the nanostructure as a whole, in turn con-
tributing to the bioaccumulation of non-functionalized BNNTs in
these organs.
In previously work, our research group conducted an in vitro
cytotoxicity study of BNNTs against normal human cells (MRC5
cells – secondary human lung ﬁbroblasts) and murine tumor cells
lineages (Ferreira et al., 2011). The results demonstrated that BNNTs
do not induce signiﬁcant cytotoxicity and oxidative stress after 48 h
incubation, conﬁrming the optimal biocompatibility and positive
evaluation of the biosafety of these nanotubes observed by Ciofani
(Ciofani et al., 2010). However, more detailed studies regarding the
bioaccumulation of BNNTs in the liver, spleen, intestines, kidneys,
and bladder is warranted to better clarify the adverse effects arising
from such an accumulation.
4.3.2. Scintigraphic imaging biodistribution study
The scintigraphic imaging biodistribution studies are shown in
Fig. 7. The results are compatible with those encountered in the ex
vivo study. Fig. 7a shows the in vivo proﬁle of BNNTs after 30 min
(post-tail injection), where the nanostructures are rapidly accumu-
lated in the liver, spleen, and gut tissues. In addition, an important
dose could be identiﬁed in the kidneys and bladder due to the elim-
ination process. After 1 h and 4 h, in Fig. 7b and c, respectively,
a slight clearance from all organs, except the bladder, as well as
an accumulation due to the excretion process, can be observed,









































sig. 7. Scintigraphic image obtained after IV administration of radiolabeled glycol c
hich is in accordance with the ex vivo study. After 24 h, the radia-
ion in animals reached a low level that prevented the acquisition
f images in a gamma  camera. The injected radiation dose would
herefore allow for the images to be obtained with relative quality.
owever, under intense elimination through the kidneys, the total
adiation in mice proved to be below the minimum required for
mage acquisition.
Considering the results encountered in ex vivo biodistribution
tudy and scintigraphic imaging, the BNNTs showed in vivo behav-
or similar to that demonstrated by others nanostructured systems
ike as polymeric micelles and gold nanoparticles showing signif-
cant renal elimination and capture by MPS  cells (De Jong et al.,
008; Koide et al., 2008). The BNNTs, with mean size of 290 ± 11 nm,
xhibit a behavior different from that observed in vivo by large
anotubes (>1000 nm)  where there is commonly the process of
gglomeration and retention in different tissues such as lungs and
eart, causing inﬂammatory responses (Qu et al., 2009). The asso-
iation of speciﬁc molecules, antibodies or aptamers on the surface
f BNNTs may  allow this system to delivery selectively therapeu-
ic agents in pathological tissues through interaction with speciﬁc
eceptors located in its cells surfaces.
. Conclusion
The ﬁndings in this study revealed that BNNTs were success-
ully synthesized using a new methodology and functionalized
ith glycol chitosan. The methodology enabled these nanostruc-
ures to have characteristics suitable for in vivo distribution studies,
here the results revealed a signiﬁcant elimination of nanostruc-
ures by renal excretion and accumulation in the liver, spleen, and
ntestines. The results showed that, 24 h after the injection, a mas-
ive reduction of radiation in the organs where the nanostructures
ad previously accumulated, in part by intense renal excretion
nd partly due to a possible metabolism of a glycol chitosan poly-
er  coating with a consequent bioaccumulation of BNNTs in the
tudied organs. The present results, together with further stud-
es, may  reveal a potential application of functionalized BNNTs as
ew potential drugs or radioisotope nanocarriers to be applied in
herapeutic procedures.
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